Drug Profile
Emprumapimod - Pfizer
Alternative Names: ARRY-371797; ARRY-797; PF-06802861; PF-07265803Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Array BioPharma
- Developer Array BioPharma; Pfizer
- Class Anti-inflammatories; Antineoplastics; Antirheumatics; Fluorobenzenes; Indazoles; Non-opioid analgesics; Small molecules
- Mechanism of Action P38 mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Ankylosing spondylitis; Cancer; Dental pain; Dilated cardiomyopathy; Musculoskeletal pain; Rheumatoid arthritis
Most Recent Events
- 03 Aug 2022 Discontinued - Phase-III for Dilated cardiomyopathy in USA (PO)
- 26 May 2022 Pfizer completes a phase I trial in Healthy volunteers in the USA (NCT05286281)
- 29 Apr 2022 Pfizer initiates enrolment in a phase I trial in Healthy volunteers in the USA (NCT05286281)